Enanta Pharmaceuticals (NASDAQ:ENTA) Earns Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Enanta Pharmaceuticals (NASDAQ:ENTA) in a research report report published on Tuesday, Benzinga reports. They currently have a $27.00 price objective on the biotechnology company’s stock. HC Wainwright also issued estimates for Enanta Pharmaceuticals’ Q4 2024 earnings at ($1.50) EPS, FY2024 earnings at ($5.62) EPS, Q1 2025 earnings at ($1.16) EPS, Q2 2025 earnings at ($1.45) EPS, Q3 2025 earnings at ($1.58) EPS, Q4 2025 earnings at ($1.67) EPS, FY2025 earnings at ($5.87) EPS, FY2026 earnings at ($8.67) EPS, FY2027 earnings at ($7.61) EPS and FY2028 earnings at ($6.97) EPS.

Several other brokerages have also recently commented on ENTA. StockNews.com upgraded shares of Enanta Pharmaceuticals from a sell rating to a hold rating in a research report on Wednesday, May 8th. JMP Securities cut their target price on Enanta Pharmaceuticals from $23.00 to $22.00 and set a market outperform rating on the stock in a research note on Tuesday, May 7th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of Hold and an average target price of $19.00.

Enanta Pharmaceuticals Stock Performance

Shares of NASDAQ ENTA traded down $0.36 during trading on Tuesday, reaching $13.13. The company had a trading volume of 11,032 shares, compared to its average volume of 216,062. The stock has a market cap of $278.08 million, a PE ratio of -2.16 and a beta of 0.60. The business’s 50 day moving average price is $13.61 and its 200-day moving average price is $13.75. Enanta Pharmaceuticals has a 52 week low of $8.08 and a 52 week high of $17.80.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($1.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.43) by $0.36. The firm had revenue of $17.97 million for the quarter, compared to the consensus estimate of $17.44 million. Enanta Pharmaceuticals had a negative return on equity of 64.85% and a negative net margin of 180.76%. The business’s revenue for the quarter was down 4.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.27) EPS. Equities analysts anticipate that Enanta Pharmaceuticals will post -5.95 earnings per share for the current year.

Insider Transactions at Enanta Pharmaceuticals

In other Enanta Pharmaceuticals news, insider Scott T. Rottinghaus sold 4,299 shares of Enanta Pharmaceuticals stock in a transaction dated Thursday, July 11th. The stock was sold at an average price of $15.07, for a total value of $64,785.93. Following the sale, the insider now owns 23,988 shares of the company’s stock, valued at approximately $361,499.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, insider Scott T. Rottinghaus sold 5,375 shares of Enanta Pharmaceuticals stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $17.08, for a total transaction of $91,805.00. Following the completion of the sale, the insider now owns 21,717 shares of the company’s stock, valued at approximately $370,926.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Scott T. Rottinghaus sold 4,299 shares of the stock in a transaction dated Thursday, July 11th. The shares were sold at an average price of $15.07, for a total transaction of $64,785.93. Following the completion of the transaction, the insider now directly owns 23,988 shares in the company, valued at $361,499.16. The disclosure for this sale can be found here. Insiders sold 16,940 shares of company stock valued at $246,181 over the last quarter. Corporate insiders own 13.64% of the company’s stock.

Hedge Funds Weigh In On Enanta Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. Federated Hermes Inc. bought a new position in Enanta Pharmaceuticals during the 4th quarter worth $1,253,000. Quest Partners LLC bought a new position in shares of Enanta Pharmaceuticals in the 4th quarter valued at $146,000. Nisa Investment Advisors LLC boosted its holdings in shares of Enanta Pharmaceuticals by 417.8% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,827 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 2,281 shares in the last quarter. Strs Ohio grew its position in Enanta Pharmaceuticals by 20.6% during the 4th quarter. Strs Ohio now owns 18,700 shares of the biotechnology company’s stock worth $175,000 after acquiring an additional 3,200 shares during the last quarter. Finally, Virtu Financial LLC bought a new stake in Enanta Pharmaceuticals during the 1st quarter worth $191,000. Institutional investors and hedge funds own 94.99% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.